三生国健股价跌5.04%，交银施罗德基金旗下1只基金重仓，持有179.45万股浮亏损失619.12万元

Group 1 - The core point of the news is that Sangfor Technologies experienced a decline of 5.04% in its stock price, reaching 64.94 CNY per share, with a trading volume of 350 million CNY and a turnover rate of 0.85%, resulting in a total market capitalization of 40.054 billion CNY [1] - Sangfor Technologies, established on January 25, 2002, and listed on July 22, 2020, is primarily engaged in the research, production, and sales of antibody drugs [1] - The company's revenue composition includes 75.24% from product sales, 15.37% from commissioned processing services, 7.94% from licensing services, and 1.44% from leasing services [1] Group 2 - According to data from the top ten holdings of funds, one fund under Jiao Yin Schroder has a significant position in Sangfor Technologies, with the Jiao Yin Medical Innovation Stock A fund increasing its holdings by 210,300 shares to a total of 1.7945 million shares, representing 3.74% of the fund's net value, making it the eighth largest holding [2] - The Jiao Yin Medical Innovation Stock A fund, established on March 23, 2017, has a current size of 2.651 billion CNY and has achieved a year-to-date return of 32.13%, ranking 1165 out of 4206 in its category [2] - The fund manager, Lou Huiyuan, has been in position for 7 years and 79 days, with the fund's total assets amounting to 4.333 billion CNY, achieving a best return of 143.65% and a worst return of -21.86% during his tenure [2]